Heron Therapeutics, INC. /De/ (HRTX) SEC Filings — 2025

Filings

• Heron's Q3 Sales Up 16%, But Debt Extinguishment Drives Net Loss Spike — 10-Q · Nov 4, 2025
• Heron Therapeutics Announces Executive & Director Compensation Changes — 8-K · Oct 29, 2025
• Heron Therapeutics Files 8-K on Shareholder Votes & Financials — 8-K · Oct 15, 2025
• Heron Therapeutics Seeks Shareholder Nod for Key Stock Issuances — DEF 14A · Sep 19, 2025
• Heron Therapeutics Files 8-K for Material Agreement — 8-K · Aug 28, 2025
• Heron Therapeutics Enters Material Agreement — 8-K · Aug 15, 2025
• Heron Therapeutics Enters Material Definitive Agreement — 8-K · Aug 12, 2025
• Heron Therapeutics Narrows Q2 Loss, Boosts Revenue by 11.7% — 10-Q · Aug 8, 2025
• Heron Therapeutics Sets 2025 Annual Meeting Date — 8-K · Jun 18, 2025
• Heron Therapeutics Files Q1 2025 10-Q — 10-Q · May 6, 2025
• Heron Therapeutics Executive Compensation Details Released — DEF 14A · Apr 30, 2025
• Heron Therapeutics Announces Board and Executive Compensation Changes — 8-K · Apr 29, 2025
• Heron Therapeutics Files 2024 10-K — 10-K · Feb 27, 2025
• Heron Therapeutics Enters Material Definitive Agreement — 8-K · Feb 20, 2025